Evidence map›Paper›PMID 35126740›Full record

ReviewJournal of smoking cessation2022

The Impact of Tobacco Use on COVID-19 Outcomes: A Systematic Review.

Jessica Baker, Nandita Krishnan, Lorien C Abroms, Carla J Berg

Abstract readReview
In one paragraph

Review in Journal of smoking cessation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jessica BakerDepartment of Global Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0003-2747-8728
Nandita KrishnanDepartment of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0003-4957-2061
Lorien C AbromsDepartment of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0001-6859-283X
Carla J BergDepartment of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0001-8931-1961

Funding

Regulatory Impact on Vape Shops and Young Adults' Use of ENDS - Diversity SupplementR01CA215155 · NCI · GEORGE WASHINGTON UNIVERSITY · PI BERG, CARLA J · 2018 to 2022
$3.4M
Market Research to Predict Emerging Tobacco Product Use in Diverse Young AdultsR01CA179422 · NCI · EMORY UNIVERSITY · PI BERG, CARLA J · 2013 to 2017
$2.7M
Smoke-free Air Coalitions in Georgia and Armenia: A Community Randomized TrialR01TW010664 · FIC · EMORY UNIVERSITY · PI BERG, CARLA J, KEGLER, MICHELLE C · 2017 to 2021
$1.5M
Emory-Georgia Clean Air Research & Education (CARE) ProgramD43ES030927 · NIEHS · EMORY UNIVERSITY · PI BERG, CARLA J, CAUDLE, WILLIAM MICHAEL · 2019 to 2025
$1.2M
Assessing IQOS Marketing Influences and Consumer Behavior in Israel: Implications for the USR01CA239178 · NCI · GEORGE WASHINGTON UNIVERSITY · PI BERG, CARLA J, LEVINE, HAGAI · 2019 to 2021
$1.2M
Recreational Marijuana Marketing and Young Adult Consumer BehaviorR56DA051232 · NIDA · GEORGE WASHINGTON UNIVERSITY · PI BERG, CARLA J, CAVAZOS-REHG, PATRICIA A · 2021 to 2021
$694k
FIC NIH HHS R01 TW010664NCI NIH HHS R01 CA179422NCI NIH HHS R01 CA215155NCI NIH HHS R01 CA239178NIDA NIH HHS R56 DA051232NIEHS NIH HHS D43 ES030927
6 · The paper itself

Abstract

introductionTobacco use increases risks for numerous diseases, including respiratory illnesses. We examined the literature to determine whether a history of tobacco use increases risks for adverse outcomes among COVID-19 patients.

methodsWe conducted a systematic search of PubMed, LitCovid, Scopus, and Europe PMC (for preprints) using COVID-19 and tobacco-related terms. We included studies of human subjects with lab-confirmed COVID-19 infections that examined tobacco use history as an exposure and used multivariable analyses. The data was collected between March 31

resultsAmong the 39 studies (33 peer-reviewed, 6 preprints) included, the most common outcome assessed was mortality (

conclusionThere is strong evidence that tobacco use increases risks of mortality and disease severity/progression among COVID-19 patients. Public health efforts during the pandemic should encourage tobacco users to quit use and seek care early and promote vaccination and other preventive behaviors among those with a history of tobacco use.

Identifiers

PMID35126740
PMCPMC8777389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.